Suppr超能文献

铸造溶剂、成膜剂和助溶剂对多晶型难溶性药物口腔分散片的影响:一项研究。

Effect of casting solvent, film-forming agent and solubilizer on orodispersible films of a polymorphic poorly soluble drug: an / study.

机构信息

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University , Cairo , Egypt.

Department of Pharmaceutics, College of Pharmacy, King Khalid University , Abha , Saudi Arabia.

出版信息

Drug Dev Ind Pharm. 2019 Nov;45(11):1751-1769. doi: 10.1080/03639045.2019.1656733. Epub 2019 Sep 2.

Abstract

In the current work, a full factorial experimental design was utilized to formulate piroxicam into orodispersible films while investigating the effects of some formulation factors on the properties of the resulting films. These factors were () the casting solvent: water and acetone/water mixture; () the film-forming agent: HPMC K4M and Na-alginate; () the solubilization system: no solubilizer, L-arginine, poloxamer and L-arginine/poloxamer mixture. Sixteen formulation runs were prepared by solvent casting method to obtain 10 mg piroxicam dosage units. Drug particle size in the prepared formulations and dissolution efficiency at 30 min were selected as responses variables. Additionally, the prepared films from each formulation were evaluated for other characters as drug content, thickness, residual water…etc. A selected formulation was then evaluated for its disintegration, palatability and stability. Utilizing acetone in the casting solution, Na-alginate as film-forming agent or both of them resulted in formation of films with larger drug particles and slower dissolution. Combined use of L-arginine and poloxamer showed better drug dissolution than using each alone. HPMC was more favorable than Na-alginate regarding mechanical properties and moisture absorption. Films from the selected formulation showed fast disintegration and acceptable palatability. These films were stable for 6 months under accelerated storage conditions. According to the computer simulation using GastroPlus™, the / behavior of piroxicam in the tested formulation was similar to that of an immediate-release formulation containing BCS class I drug. The selected formulation is therefore would satisfy the WHO perquisites for applying the biowaiver.

摘要

在本工作中,采用完全析因实验设计将吡罗昔康制成口腔崩解片,同时考察了一些制剂因素对所得薄膜性质的影响。这些因素是()浇铸溶剂:水和丙酮/水混合物;()成膜剂:HPMC K4M 和 Na-藻酸盐;()增溶系统:无增溶剂、L-精氨酸、泊洛沙姆和 L-精氨酸/泊洛沙姆混合物。通过溶剂浇铸法制备了 16 个制剂运行,以获得 10mg 吡罗昔康剂量单位。药物在制剂中的粒径和 30 分钟的溶出效率被选为响应变量。此外,还对每种制剂的制备薄膜进行了其他特性评估,如药物含量、厚度、残留水分等。然后,对选定的制剂进行崩解、口感和稳定性评估。在浇铸溶液中使用丙酮,或使用 Na-藻酸盐作为成膜剂,或两者同时使用,都会导致药物颗粒变大、溶解速度变慢。L-精氨酸和泊洛沙姆的联合使用比单独使用时具有更好的药物溶解效果。与 Na-藻酸盐相比,HPMC 具有更好的机械性能和吸湿性。从选定的制剂中得到的薄膜具有快速崩解和可接受的口感。这些薄膜在加速储存条件下 6 个月内稳定。根据使用 GastroPlus™进行的计算机模拟,所测试制剂中吡罗昔康的/行为与含有 BCS 类 I 药物的即刻释放制剂相似。因此,选定的制剂将满足世界卫生组织应用生物豁免的要求。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验